New Therapy Shows Promise For PIK3CA-Related Overgrowth Spectrum in Retrospective Study
source: pixabay.com

New Therapy Shows Promise For PIK3CA-Related Overgrowth Spectrum in Retrospective Study

Data has recently been announced from a study investigating the efficacy of a new therapy called Alpelisib, for the treatment of PIK3CA-related overgrowth spectrum (PROS). The study was called EPIK-P1.…

Continue Reading New Therapy Shows Promise For PIK3CA-Related Overgrowth Spectrum in Retrospective Study

Japan’s Ministry of Health, Labour and Welfare Has Just Announced Their Approval of Alofisel for Crohn’s Disease

Japan's Ministry of Health, Labour, and Welfare has just announced its approval of Alofisel, a stem cell therapy created by Takeda. This approval is specifically for patients who are diagnosed…

Continue Reading Japan’s Ministry of Health, Labour and Welfare Has Just Announced Their Approval of Alofisel for Crohn’s Disease
CUREPSP Gives Four New Grants for “Prime of Life” Neurodegenerative Diseases
source: pixabay.com

CUREPSP Gives Four New Grants for “Prime of Life” Neurodegenerative Diseases

CurePSP has just announced their latest Venture Grant recipients. These grants total $320,000 and will all support the research of neurodegenerative disease treatments. CurePSP gives these grants twice every year.…

Continue Reading CUREPSP Gives Four New Grants for “Prime of Life” Neurodegenerative Diseases

New Therapy for Eosinophilic Granulomatosis with Polyangiitis May be Coming to Europe

The EMA has recently published their recommendation for extending the indication of a treatment called Nucala to include patients diagnosed with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Specifically,…

Continue Reading New Therapy for Eosinophilic Granulomatosis with Polyangiitis May be Coming to Europe
Study Finds Metabolic Syndrome is Not Associated with Death for Chronic Kidney Disease Patients
source: pixabay.com

Study Finds Metabolic Syndrome is Not Associated with Death for Chronic Kidney Disease Patients

A recent study has investigated the association between cardiovascular disease risk factors and fat distribution. Researchers used linear regression analyses and adjusted for insulin sensitivity and other factors. Previous research…

Continue Reading Study Finds Metabolic Syndrome is Not Associated with Death for Chronic Kidney Disease Patients
The 2021 Rare Disease Week Discussed Policies Which Could Improve The Lives of Rare Disease Patients
Proulain / Pixabay

The 2021 Rare Disease Week Discussed Policies Which Could Improve The Lives of Rare Disease Patients

Rare Disease Week this year was July 14th-22nd and held virtually. With over 600 participates advocating for those living with a rare disease diagnosis and 250 patient organizations, this event’s…

Continue Reading The 2021 Rare Disease Week Discussed Policies Which Could Improve The Lives of Rare Disease Patients

Combination Therapy Could Be New Nasopharyngeal Carcinoma Standard of Care

A recent Phase 3 clinical trial published in Lancet Oncology has identified that camrelizumab used in combination with gemcitabine and cisplatin (chemotherapy) improves progression-free survival (PFS) for those diagnosed with recurrent or…

Continue Reading Combination Therapy Could Be New Nasopharyngeal Carcinoma Standard of Care
Sleep Deprivation Functioning Deficits Can Last For Over a Week, New Study Finds
emrahozaras / Pixabay

Sleep Deprivation Functioning Deficits Can Last For Over a Week, New Study Finds

A recent study investigated the lingering effects of sleep deprivation in healthy adults. This study was conducted by Jeremy Ochab from Poland, alongside his colleagues. Sleep Deprivation Sleep deprivation or…

Continue Reading Sleep Deprivation Functioning Deficits Can Last For Over a Week, New Study Finds
Second-Ever Therapy for Waldenström’s Macroglobulinemia is Now FDA Approved
source: pixabay.com

Second-Ever Therapy for Waldenström’s Macroglobulinemia is Now FDA Approved

The FDA has just announced their approval of zanubrutinib (Brukinsa) as a therapeutic option for Waldenström's macroglobulinemia. This approval was given based on the ASPEN Phase 3 clinical trial, and…

Continue Reading Second-Ever Therapy for Waldenström’s Macroglobulinemia is Now FDA Approved

Atezolizumab and Bevacizumab Improves Survival With Unresectable Hepatocellular Carcinoma

New treatments for unresectable hepatocellular carcinoma (HCC) were approved based on a Phase 3 clinical trial. Richard Kim has recently provided an overview of this study. The Study This study ultimately…

Continue Reading Atezolizumab and Bevacizumab Improves Survival With Unresectable Hepatocellular Carcinoma